In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Jack Crawford, CEO, Demeetra Magnus Gustafsson, Chief Commercial Officer, NorthX Biologics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

From sequence to scale: Gene editing’s new era in biologics manufacturing

BioSpace

Hi, my name is Jennifer Smith-Parker, Director of Insights at BioSpace, and you're listening to Denatured. In this episode, you'll hear from Jeff Axe, CEO of Demetra, and Magnus Gustafsson, Chief Commercial Officer at NorthX Biologics. We unpack the evolution of cell line development, CHO cells, targeted integration, transposases, and the collaboration models speeding biologics from sequence to GMP.

Hi, Jack and Magnus. Thank you so much for joining this episode of Denatured. If you can introduce yourselves, that would be great.

Hi, I'm Jack Crawford. I'm the CEO of Demetra. I've been running startup gene editing technology companies for about the last 17 years. Demetra is a gene editing platforms technology company, and we're focusing on engineering CHO cells for cell line development and biomanufacturing. Thank you so much, Jack. Magnus?

And my name is Magnus Gustafsson. I'm the Commercial Officer for NorthX Biologics. That's a CDMO based in Sweden. And I have a scientific background, I would still argue. I started out my career developing monoclonal antibodies and other proteins. I've moved into business development and now work at NorthX Biologics with those services. Perfect. Well, thank you so much, gentlemen.

So let's start at the very basics here for our audience who may not be as familiar with some of the technical language. So what is cell line development and why is it such a critical step in biologics manufacturing? Thank you. So before we get into cell line development, I thought I would talk about the step before. This is the discovery. So there's a bunch of types of drug modalities, but what we're talking about is biologics.

From sequence to scale: Gene editing’s new era in biologics manufacturing

Read the full transcript

The candid version is on a podcast,
not the earnings call.

From sequence to scale: Gene editing’s new era in biologics manufacturing

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.